Braidwell LP Buys New Position in Heartflow, Inc. $HTFL

Braidwell LP purchased a new position in Heartflow, Inc. (NASDAQ:HTFL) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $1,683,000.

Other institutional investors and hedge funds have also modified their holdings of the company. TFC Financial Management Inc. bought a new stake in shares of Heartflow during the 3rd quarter valued at $40,000. Legal & General Group Plc bought a new position in Heartflow in the 3rd quarter worth $59,000. Y Intercept Hong Kong Ltd purchased a new position in Heartflow during the third quarter valued at $234,000. Legato Capital Management LLC bought a new stake in Heartflow during the third quarter valued at about $243,000. Finally, Sandia Investment Management LP bought a new position in shares of Heartflow in the third quarter worth about $252,000.

Heartflow Stock Performance

Shares of HTFL stock opened at $20.49 on Friday. The stock has a fifty day simple moving average of $27.66 and a two-hundred day simple moving average of $30.69. The firm has a market capitalization of $1.74 billion and a PE ratio of -11.32. Heartflow, Inc. has a 52-week low of $20.13 and a 52-week high of $41.22.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on HTFL shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $40.00 price objective on shares of Heartflow in a research report on Monday, March 9th. Wells Fargo & Company initiated coverage on shares of Heartflow in a research note on Wednesday, January 28th. They set an “overweight” rating and a $38.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Insider Activity

In related news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the sale, the insider owned 10,448,158 shares of the company’s stock, valued at approximately $293,070,831.90. This trade represents a 16.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Julie A. Cullivan sold 9,122 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $25.00, for a total value of $228,050.00. Following the completion of the transaction, the director directly owned 27,291 shares in the company, valued at approximately $682,275. This represents a 25.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,117,674 shares of company stock valued at $59,052,646 in the last three months.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.